<DOC>
	<DOCNO>NCT00117936</DOCNO>
	<brief_summary>Treatment no-option heart patient coronary artery disease . Procedure include injection heart protein growth factor , administer Cordis Corp. MyoStar injection catheter , stimulate growth blood vessel around block coronary artery .</brief_summary>
	<brief_title>Fibroblast Growth Factor-1 ( FGF-1 ) Treatment Coronary Heart Disease</brief_title>
	<detailed_description>Patients chronic , stable angina document coronary artery disease eligible study .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion criterion 1 . Sign inform consent form . 2 . Age ≥25 ≤75 year , either gender , race . 3 . At least 3 month history chronic , stable angina relieve rest and/or nitroglycerin . 4 . Documented symptomatic CCS Angina Classification III IV despite use optimal medical therapy note Inclusion Criterion 10 . 5 . Pattern CHD ( coronary pathology ) percutaneous interventional therapy and/or CABG recommend treat cardiologist . This decision document basis either complicate vessel physiology and/or lack suitable target vessel PTCA CABG , past history complication . 6 . One/two/three vessel disease evidence either angiographic documentation advance atherosclerotic narrow ≥60 % least one major epicardial coronary artery ( right coronary artery [ RCA ] , leave circumflex [ LCX ] , LAD [ branch ] ) , diffuse type CHD evidence appearance coronary angiography multiple stenosis , multiple atherosclerotic plaque , and/or peripheral occlusion ( ) coronary vessel ( ) without history MIs . 7. demonstrate radionuclide angiographically determine leave ventricular ejection fraction ( LVEF ) ≥30 % . 8 . Preoperative proof reversible ischemia . 9 . No evidence proliferative retinopathy significant nonproliferative retinopathy . 10. must optimal medical therapy least 2 month prior enter study , document medical history . This include medical management , subject must enter study least one follow medication : betablockers , calcium entry blocker , ranolizine , longacting nitrate . 11 . Exercise duration qualify treadmill test Visit 1 Visit 2 ≥3 ≤9 minute modify Bruce protocol . 12 . Exercise duration qualify treadmill test Visits 1 2 must satisfy least one two follow condition : ( ) differ less equal 20 % long time ; ( b ) differ less equal 60 second . Subjects whose ETTs Visits 1 2 satisfy least one two condition allow third ETT , investigator 's discretion , 5 7 day Visit 2 . If third ETT do , compare second ETT must satisfy least one two condition . 13 . For treadmill test result support inclusion must terminate presence angina either follow reason : ( ) angina becomes severe continue test AND must horizontal depression downsloping STsegment least 1 mm measure 80 m J point subsequently establish Biomedical Systems central ECG lab , ( b ) angina grade AND must horizontal depression downsloping STsegment measure 80 m J point 2 mm exercise . The qualifying time treadmill test time horizontal depression downsloping STsegment 1 mm compare preexercise ST segment subsequently establish Biomedical Systems central ECG lab . 14 . A forced vital capacity ( FVC ) ≥30 % . 15 . A negative pregnancy test woman childbearing potential Screening . 16 . Female subject must postmenopausal sterilize , childbearing potential , breast feeding , intention become pregnant course study , use contraceptive drug device . 17 . Negative cancer screening test accord American Cancer Society ( [ ACS ] Appendix 13.8 ) . 18 . Ability complete study compliance protocol . Exclusion criteria 1 . History undergoing CABG , PTCA TMR evidence acute MI last 3 month . 2 . Subjects malignancies history malignancy ( exception basal cell carcinoma [ BCC ] skin ) exclude study . Those subject history BCC eligible enrollment , monitor qualified dermatologist every 8 week period 6 month evaluation skin condition . Subjects exist BCC exclude study . 3 . Evidence concurrent clinically significant infection ( e.g . elevate white blood cell [ WBC ] count &gt; 13,000 x 109/L , temperature &gt; 38.5°C ) , evidence `` common cold '' `` flu . '' 4 . Concomitant structural heart disease , moderate severe heart valve disease , congenital heart disease , etc . evidence congestive heart failure directly relate past ischemic event . 5 . Left ventricular thrombus ( mobile muralbased ) evidence ventriculogram echocardiography . 6 . Creatine kinase ( CK ) level &gt; 3 x upper limit normal ( ULN ) . 7 . Renal insufficiency require dialysis laboratory evidence serum creatinine &gt; 2.0 mg/dL . 8 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x ULN . 9 . History coagulation disorder abnormal prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN , thrombocytopenia ( &lt; 100,000/µl ) , ongoing anticoagulant therapy ( exception aspirin , 85 mg/day ) . 10 . History blood cell disease . 11 . Poorly control insulindependent diabetes mellitus ( HbA1c &gt; 8 % ) 12 . Preexisting retinal disease , include proliferative retinopathy , severe nonproliferative retinopathy . 13 . Use illicit recreational drug within past year . 14 . A positive test result human immunodeficiency virus ( HIV ) antibody . 15 . Screening ECG result demonstrate recent evidence transmural ischemia . 16 . Clinically significant ECG abnormality , e.g . : QRS duration &gt; 0.12 second ; QTc &gt; 450 m male &gt; 460 ms female ; Highgrade trioventricular ( AV ) block ; Left bundle branch block ( LBBB ; Left ventricular hypertrophy ( LVH ) secondary STT change ; Frequent , recurrent , sustain ventricular arrhythmia ; Resting ST segment depression &gt; 1 mm ( measure 80 ms beyond J point ) baseline . 17 . Subjects concomitant lifethreatening disease life expectancy estimate less 2 year . 18 . Any condition opinion investigator would interfere participant 's ability provide inform consent comply study instruction , possibly confound interpretation study result , endanger participant take part trial . 19 . Use investigational drug , device product , participation drug research study within period 30 day prior receive IMP . 20 . Any subject unstable angina . 21 . Heart failure New York Heart Association ( NYHA ) Functional Class III IV . 22 . Uncontrolled hypertension preclude exercise test and/or contribute angina severity ( systolic blood pressure [ SBP ] &gt; 200 mmHg diastolic blood pressure [ DBP ] &gt; 110 mmHg ) , significant hypotension ( SBP &lt; 90 mmHg DBP &lt; 60 mmHg ) . 23 . Subjects currently External Counter Pulsation therapy receive therapy within 3 month prior screen date . 24 . Any mobility pulmonary complication impedes subject 's ability perform exercise stress test . 25 . Total fasting serum cholesterol &gt; 200 mg/dL ( level great equal 200 mg/dL , additional medical intervention initiate bring level 200 mg/dL ) . 26 . History heparininduced thrombocytopenia . 27 . Subjects history recurrent symptomatic atrial fibrillation significant ventricular arrhythmia . 28 . Aortic mitral valve replacement . 29 . Subjects undergone heart transplantation . 30 . Medical history physical examination display evidence catheterization contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>No-option heart patient</keyword>
	<keyword>Blocked coronary artery</keyword>
	<keyword>Revascularization</keyword>
	<keyword>FGF-1</keyword>
	<keyword>growth factor</keyword>
</DOC>